PGT-A Embryo Biopsy: Risks, Consent and Questions Before Genetic Testing

PGT-A is commonly performed on blastocyst-stage embryos by removing a small number of cells from the outer layer, which later contributes to supporting tissues. The cells are sent for genetic analysis while embryos are managed by the embryology laboratory. The sampled cells are not every cell of the embryo. This creates an important limitation: a result may not perfectly describe the embryo as a whole. The embryology team should explain which embryos are considered suitable for biopsy and the process used by its laboratory.

Reports may include euploid, aneuploid, mosaic or uninterpretable classifications depending on technology and laboratory thresholds. An inconclusive result is not proof that an embryo is abnormal. Mosaic findings deserve specialist interpretation because sampled cells may differ from others. Ask the laboratory and genetics team what each label means, how often repeat testing is contemplated, and what the clinic’s policy is for counselling about embryos that receive a mosaic result. Avoid making an irreversible disposal decision from an internet chart.

Careful biopsy can be performed successfully, but embryo damage is a possible risk. Errors or biological sampling limitations can also lead to false reassurance or exclusion of potentially viable embryos. Genetic testing may reduce certain risks for selected patients without guaranteeing pregnancy or removing all causes of miscarriage. Patient selection matters; evidence for improved live birth in an unselected IVF population is not established. Ask whether the recommended testing addresses a specific clinical question rather than a blanket add-on sales package.

PGT-A screens chromosome number. PGT-M aims to identify a specific monogenic condition when there is a known genetic indication, while PGT-SR relates to structural chromosomal rearrangements. The tests differ in why they are offered, their laboratory preparation and counselling needs. A family history or carrier-screening result may justify genetic counselling even when PGT-A is not indicated. Ask whether the clinic is recommending the right test for the clinical question and what subsequent prenatal testing may still be appropriate.

Patients should be told about costs, biopsy and freezing procedures, storage consent, reporting timelines, data privacy and policies on untested, mosaic or inconclusive embryos. Ask who makes final disposition decisions and whether a second opinion is available before irreversible choices. Genetic information is sensitive; request clarity about laboratory data sharing and retention. Even after an embryo is reported euploid, pregnancy screening and diagnostic options should be discussed with obstetric and genetic professionals as appropriate.

HomeIVF describes doctor-led fertility care with teleconsultations and selected home support where available. That can help patients prepare genetic counselling questions and understand their reports. Egg retrieval, fertilisation, blastocyst culture, embryo biopsy, freezing, thawing and transfer are laboratory and clinic procedures, never home procedures. A doctor should confirm any home blood collection or prescribed-injection support available locally without suggesting that embryo genetic testing can be performed at home.

Ask your clinician to write down the working diagnosis, which evidence supports it, the treatment options discussed and what result would actually change the plan. Confirm whether both partners have been appropriately assessed, what tests are necessary rather than merely available, who reviews time-sensitive findings and what happens when a cycle does not go as hoped. Request a complete estimate of investigation, medication, monitoring, facility and laboratory charges. Decisions should be framed as informed choices under uncertainty rather than sales deadlines or promised success.

HomeIVF is a doctor-led, home-supported fertility-care model intended to reduce unnecessary clinic visits rather than replace clinical IVF. Depending on medical needs and confirmed local availability, teleconsultations, selected home blood collection and help administering prescribed injections may be possible. None is promised for every patient or location. Required ultrasounds and examinations, clinical IUI, sperm retrieval, egg retrieval, embryology and embryo transfer must take place in appropriate facilities. Home services must follow the treating clinician’s orders and the laboratory’s timing and quality requirements. A patient with urgent symptoms needs an appropriate emergency service, not an online appointment.